. .

-

. . ,
. . . , -

30 (), 1986 ., . , [1]. ( ). ( ) (), ( ), ( ). , (). , , . (, , ). : , , , , . , .

, , , :

• - ;
• ;
• - ( );
• ( ), ;
• ( , ), , ;
• , , ;
• , .

:

• ;
• ;
• ( , - ), , , ( ), ;
• , , ;
• .

, і. : (, ) , , / . . . . , . 10 [2]. , , 1965 , . μ- , , 90100 . , , . , (336,5 ), , . . , , . . 92% [3]. .

. 80- ( /ravioli systems) .

, ( ) . (, ) ( . .). , . / . . , , . . . , . , . - - () ( ). , [47].

, , . , . , . .

, , . ( ) 3 . 4,2 ² ( 12,5 /), 8,4 ² ( 25 /), 16,8 ² ( 50 /), 25,2 ² ( 75 /), 33,6 ² ( 100 /). 1,38, 2,75, 5,50, 8,25, 11,0 , . , (. 1).

12, 25, 50, 75 100 . 0,3 (300 ), 0,6 (600 ), 1,2 (1200 ), 1,8 (1800 ) 2,4 (2400 ). 0,31,5 /. 1224 , 33,5 38 .

72 . 47% 24 , 68% 48 94% 72 . .

[8, 9]. , - , . , 70100 , . . 2 , .

, 30 15 10 . .

.

, , [1117]. , , , . [1822] [23, 24]. , , , . , , - , , WOMAC, . , 1175 20 2012 32 , II III ( ).

, , , , , , , , , ( , ) . [25, 26]. , , , , . . , , , , , . , - , , m- [27]. , . , S. F. Butler . [28] . , , . , , , , [29]. , .

, , (, ).

, - . [30, 31]. , , N 1481/-88. 9 1175 20 2012 386 30 2015 . N 1481/-88 21 2015 . , . N 1481/-88 . 501- 31.12.2014 () , , , , .

, , . , , . , , , .

1. Caraceni A., Hanks G., Kaasa S. et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC // Lancet Oncol. 2012, Feb; 13 (2): e 5868.
2. . ., . . // . 2011, 6. . 3942.
3. Varvel J. R., Shafer S. L., Hwang S. S. et al. Absorbtion characteristics of transdermally administered fentanyl // Anesthesilogy. 1989; 43: 155162.
4. Freynhagen R., von Giesen H. J., Busche P. et al. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain // J Pain Symptom Manage. 2005, Sep; 30 (3): 289297.
5. Marier J. F., Lor M., Potvin D. et al. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects // J Clin Pharmacol. 2006, Jun; 46 (6): 642653.
6. Marier J. F., Lor M., Morin J. et al. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation // Br J Clin Pharmacol. 2007, Jan; 63 (1): 121124.
7. Sathyan G., Guo C., Sivakumar K. et al. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications // Curr Med Res Opin. 2005, Dec; 21 (12): 19611968.
8. Kress H. G., Boss H., Delvin T. et al. Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequvivalent // Eur. J. of Pharmaceutics and Biopharmaceutics. 2010; 75: 225231.
9. Kress H. G., von der Laage D., Hoerauf K. H. et al. A Randomized, Open, Parallel Group, Multicenter Trial to Investigate Analgesic Efficacy and Safety of a New Transdermal Fentanyl patch Compared to Standart opioid Treatment in Cancer Pain // J. of Pain and Symptom Management. 2008; Vol. 36, 3, 268279.
10. Elsner F., Radbruch L., Sabatowski R. et al. Switching opioids to transdermal fentanyl in clinical setting // Schmerz. 1999; 133: 273278.
11. . . // . 2007, 12, . 7073.
12. . . . .: , 2011. 384 c.
13. . ., . . . . ., 2005. 83 .
14. . . . .: -, 2013. 248 .
15. . ., . ., . . . / . 2015. .: . . . . 48 .
16. Mystakidou K., Parpa E., Tsilika E. et al. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers // J. Pain. 2004; 5: 119132.
17. Skaer T. L. Transdermal opioids for cancer pain // Health Qual. Life Outcomes. 2006, Mar 31; 4: 24.
18. . . // . 2008, 16, .
19. . ., . ., . . - - , // . 2010; 2, . 100104.
20. . . // .
21. Langford R., McKenna F., Ratcliffe S. et al. Transdermal Fentanyl for Imrovement of Pain and Functioning in Osteoartrithis // Arthritis&Rheumatism. 2006, vol. 54, 6, p. 18291837.
22. Theoridis T., Waap I., Schwalen S. et al. Fentanyl TTS in the treatment of pain caused by arthrosis // Z. Orthop. Ihre Grenzgeb. 2003, Mar-Apr; 141 (2): 217222.
23. . ., . ., . . - - ( // , , , 2009; 34, . 4752.
24. Simpson R. K. Jr., Edmondson E. A., Constant C. F. et al. Transdermal fentanyl as treatment for chronic low back pain // Pain Symptom Manage.1997, Oct; 14 (4): 218224.
25. Canneti A., Luzi M., Di Marco P. et al. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients // Minerva Anestesiol. 2013, Aug; 79 (8): 871883.
26. Agarwal S., Polydefkis M., Block B. et al. Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states // Pain Med. 2007, Oct-Nov; 8 (7): 554562.
27. Tassinari D., Sartori S., Tamburini E. Adverse Effects of Transdermal Opiates Treating ModerateSevere Cancer Pain in Comparison to Long-Acting Morphine: A Meta-Analysis and Systematic Review of the Literature // J. of Palliative Medicine. 2008; Vol. 11, 3: 492501.
28. Butler S. F., Benoit C., Budman S. H. et al. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers // Harm Reduct J. 2006, Feb 2: 3: 5.
29. . ., . . // . 2014. . 23. 5. . 8083.
30. Lilleng P. K., Mehlum L. I., Bachs L., Morild I. Deaths after intravenous misuse of transdermal fentanyl // Forensic Sci. 2004, Nov; 49 (6): 13641366.
31. Tharp A. M., Winecker R. E., Winston D. C. Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches // Am J Forensic Med Pathol. 2004, Jun; 25 (2): 178181.
32. . ., . ., . ., . . , , - . .: , 2015. 72 .